BiotechTube
Home/Pipeline/MV-010

MV-010

Inflammatory Bowel Disease (IBD)

PreclinicalActive

Key Facts

Indication
Inflammatory Bowel Disease (IBD)
Phase
Preclinical
Status
Active
Company
MV BioTherapeutics

About MV BioTherapeutics

MV BioTherapeutics is a private, preclinical-stage biotech leveraging novel microbiome-based platforms to develop therapeutics for enteric and systemic diseases. Its ApyraMed platform uses apyrase enzymes to improve intestinal fitness and immune competence, targeting inflammatory bowel disease and cancer. The ApyraVax platform is designed to elicit potent mucosal IgA responses against pathogens, positioning the company in the growing fields of microbiome therapeutics and mucosal vaccines.

View full company profile

Therapeutic Areas

GastroenterologyOncologyInfectious Diseases

Other Inflammatory Bowel Disease (IBD) Drugs

DrugCompanyPhase
HBM2001Harbour BioMedDiscovery
Metabolite Delivery Platform (Therapeutic Programs)ClostraBioPre-clinical
ABO21009AboleIIs PharmaPhase 1
GlyHealth BiomarkersAvennaPre-clinical/Validation
GTI-850GSNO TherapeuticsPre-clinical
CK-0045Cytoki PharmaPre-clinical/Research
NM81Numab InnovationPre-clinical
LIAISON® CalprotectinDiaSorinCommercial
SL-325Shattuck LabsPhase 2
SL-425Shattuck LabsPhase 1
VE202PureTech HealthPhase 2